| Product NDC: | 76237-131 |
| Proprietary Name: | Carvedilol |
| Non Proprietary Name: | Carvedilol |
| Active Ingredient(s): | 3.125 mg/1 & nbsp; Carvedilol |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 76237-131 |
| Labeler Name: | McKesson Contract Packaging |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA078227 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20110920 |
| Package NDC: | 76237-131-30 |
| Package Description: | 6 BLISTER PACK in 1 BOX, UNIT-DOSE (76237-131-30) > 5 TABLET, FILM COATED in 1 BLISTER PACK |
| NDC Code | 76237-131-30 |
| Proprietary Name | Carvedilol |
| Package Description | 6 BLISTER PACK in 1 BOX, UNIT-DOSE (76237-131-30) > 5 TABLET, FILM COATED in 1 BLISTER PACK |
| Product NDC | 76237-131 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Carvedilol |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20110920 |
| Marketing Category Name | ANDA |
| Labeler Name | McKesson Contract Packaging |
| Substance Name | CARVEDILOL |
| Strength Number | 3.125 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Adrenergic alpha-Antagonists [MoA],Adrenergic beta1-Antagonists [MoA],Adrenergic beta2-Antagonists [MoA],alpha-Adrenergic Blocker [EPC],beta-Adrenergic Blocker [EPC] |